Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Bosentan 32 mg Dispersible Tablets vs Tracleer in Healthy Subjects
NCT06484673Phase 1Completed
- Sponsor
- Humanis
- Start
- Apr 2024
- Primary completion
- May 2024
- Modality
- Nucleic Acid-Directed Small Molecules, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of bosentan in pulmonary arterial hypertension (PAH) (2 arms), sponsored by Humanis. Primary endpoints: Maximum concentration obtained at 23 hours and AUC from time 0 to last collection time t at 23 hours. Started Apr 2024; status: completed.
02
Drugs
bosentan
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT06484673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06484673.